Our proprietary platform leverages Second Harmonic Generation (SHG) to measure structural changes of biomolecules in real time and with high throughput. Biomolecules undergo conformational changes that regulate activity and impact how they interact with other molecules in a pathway. By combining knowledge about a drug target’s native and disease-relevant biology with our platform, we can efficiently discover and develop molecules that induce functionally relevant structural changes in difficult-to-drug targets. Therefore, our drugs treat disease by inducing the desired conformational state in a key target.
We are partnering with other biopharma to drive discovery and development of novel therapeutics for challenging targets.Partner with Us!
BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop novel therapeutic molecules against challenging, high-value drug targets. We have a passionate and experienced team with unique expertise on developing structural assays across a broad range of target classes.
Our investors include 5AM Ventures, Pfizer Ventures, and Alexandria Venture Investments. We are headquartered in South San Francisco, CA.Learn More
JOB DESCRIPTION: We are seeking a talented and highly-motivated Scientist/Sr. Scientist to join our collaborative discovery team to support small-molecule hit discovery using BlueLight Therapeutics’s proprietary technology for measuring protein structural changes. As a part of the team, they will play a central role in defining and executing on strategies to design small-molecule screening assays […]
JOB DESCRIPTION: We are seeking a talented and highly-motivated Research Associate/Sr. Research Associate to join our collaborative discovery team to support small-molecule hit discovery using BlueLight Therapeutics’s proprietary technology for measuring protein structural changes. As a part of the team, they will play a central role in protein expression and purification, developing biochemical and biophysical […]
New company brand identity and Chief Scientific Officer appointment reflect long-term focus on developing small molecule therapeutics that regulate conformation of challenging drug targets SOUTH SAN FRANCISCO, Calif. – May 27, 2020 – Biodesy Inc. today announced that it has changed its corporate name to BlueLight Therapeutics Inc., effective May 20, 2020, and appointed […]